Provided by Tiger Trade Technology Pte. Ltd.

Roivant Sciences Ltd.

34.64
-0.0700-0.20%
Post-market: 34.640.00000.00%16:01 EDT
Volume:35.08M
Turnover:1.21B
Market Cap:25.02B
PE:-73.70
High:35.34
Open:34.65
Low:34.02
Close:34.71
52wk High:37.97
52wk Low:11.94
Shares:722.41M
Float Shares:581.00M
Volume Ratio:6.14
T/O Rate:6.04%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4700
EPS(LYR):-0.5400
ROE:-8.52%
ROA:-16.48%
PB:5.91
PE(LYR):-64.15

Loading ...

Roivant Sciences price target raised to $34 from $30 at Jefferies

TIPRANKS
·
Apr 07

Roivant Sciences (ROIV) Is Up 6.8% After Mixed Autoimmune Trial Updates - Has The Bull Case Changed?

Simply Wall St.
·
Apr 04

Immunovant CEO Eric Venker disposes of common shares worth $8.5 million

Reuters
·
Apr 04

Ro says working with Eli Lilly to launch Zepbound KwikPen

TIPRANKS
·
Apr 03

BRIEF-Ro Says Working With Eli Lilly To Launch Zepbound Kwikpen Nationwide On Its Platform

Reuters
·
Apr 03

Immunovant says Phase 3 batoclimab trials miss primary endpoint in thyroid eye disease

Reuters
·
Apr 02

Roivant’s Priovant starts Phase 2b/3 brepocitinib trial in lichen planopilaris

Reuters
·
Apr 02

Roivant Sciences Ltd - Phase 3 Studies of Batoclimab in Ted Fail to Meet Primary Endpoint

THOMSON REUTERS
·
Apr 02

Roivant Sciences Ltd: Topline Phase 3 Data in Niu and Phase 3 Study Initiation in Cs Are Expected in Second Half of Calendar Year 2026

THOMSON REUTERS
·
Apr 02

Roivant Announces Expansion of Brepocitinib Development Program With New Phase 2B/3 Trial in Lichen Planopilaris (Lpp) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (Ted)

THOMSON REUTERS
·
Apr 02

Roivant Sciences Ltd - Ted Study Patients Show Greater Proptosis Improvement After High-Dose Period

THOMSON REUTERS
·
Apr 02

Roivant director Meghan FitzGerald disposes of common shares worth $1.92 million

Reuters
·
Mar 31

S&P 500 Futures Climb In Premarket Trading; United Therapeutics, Alcoa Lead

Dow Jones
·
Mar 30

Assessing Roivant Sciences (ROIV) Valuation After Brepocitinib Priority Review And Phase 3 VALOR Success

Simply Wall St.
·
Mar 29

BRIEF-New England Journal Of Medicine Publishes Positive Phase 3 Valor Trial Results Of Brepocitinib In Dermatomyositis

Reuters
·
Mar 29

Roivant’s brepocitinib beats placebo in Phase 3 dermatomyositis trial, NEJM reports

Reuters
·
Mar 29

Roivant Sciences Ltd - FDA Grants Priority Review to Brepocitinib Nda With Pdufa Date in Q3 2026

THOMSON REUTERS
·
Mar 29

New England Journal of Medicine Publishes Positive Phase 3 Valor Trial Results of Brepocitinib in Dermatomyositis

THOMSON REUTERS
·
Mar 29

Should Roivant’s Moderna Settlement Shift Investor Focus to Pipeline Execution Risks for Roivant Sciences (ROIV)?

Simply Wall St.
·
Mar 28

Roivant Sciences files Form 8-K/A to add Moderna settlement agreement exhibit

Reuters
·
Mar 23